Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc.（IMDX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · IMDX · 截至 2025年9月30日
股东结构概览
27
机构持有人数
▼ 3 vs Q2
$54.05M
机构持仓总市值
▲ $5.14M vs Q2
26.84M
总流通股
freeFloat 27.15%
16.28M
13F 申报持股数
▲ 1.02M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
IMDX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BROADWOOD CAPITAL INC in vitro & in vivo diagnostic substances | 11.41M | 35.62% | 35.62% | $37.88B | Nov 14, 2025 | — held |
AWM INVESTMENT COMPANY, INC. in vitro & in vivo diagnostic substances | 2.82M | 8.81% | 8.81% | $9.37B | Nov 13, 2025 | — held |
PURA VIDA INVESTMENTS, LLC in vitro & in vivo diagnostic substances | 947.1K | 2.96% | 2.96% | $3.14B | Nov 12, 2025 | ▲ 928.4K |
VANGUARD GROUP INC in vitro & in vivo diagnostic substances | 486.7K | 1.52% | 1.52% | $1.62B | Nov 7, 2025 | ▲ 3.0K |
GEODE CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 198.5K | 61.95% | 61.95% | $658.94M | Nov 12, 2025 | ▲ 40.9K |
BLACKROCK, INC. in vitro & in vivo diagnostic substances | 88.0K | 27.46% | 27.46% | $292.00M | Nov 12, 2025 | ▲ 1.5K |
MILLENNIUM MANAGEMENT LLC in vitro & in vivo diagnostic substances | 73.3K | 22.88% | 22.88% | $243.33M | Nov 14, 2025 | ▲ 55.8K |
MORGAN STANLEY in vitro & in vivo diagnostic substances | 62.2K | 19.42% | 19.42% | $206.53M | May 27, 2026 | — held |
FNY INVESTMENT ADVISERS, LLC in vitro & in vivo diagnostic substances | 53.1K | 16.57% | 16.57% | $176.00M | Dec 15, 2025 | ▲ 28.4K |
STATE STREET CORP in vitro & in vivo diagnostic substances | 41.9K | 13.07% | 13.07% | $138.96M | Nov 14, 2025 | ▲ 22.3K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
8
增持
+1.09M 股1
新建仓
首次建仓7
减持
−39.1K 股4
清仓
完全退出净股数变化（前50家）
+1.05M
+1.09M / −39.1K
净新增持仓人
-2
新建 1 个 / 退出 4 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
IMDX 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
12
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 27, 2026 | Purchase | 250,923 | $3.64 | $913.1K | 12.68M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 27, 2026 | Purchase | 0 | — | — | 12.68M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 24, 2026 | Purchase | 38,880 | $3.53 | $137.1K | 12.43M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 24, 2026 | Purchase | 0 | — | — | 12.43M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 23, 2026 | Purchase | 280,381 | $3.50 | $982.0K | 12.40M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 23, 2026 | Purchase | 0 | — | — | 12.40M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 20, 2026 | Purchase | 0 | — | — | 12.11M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 20, 2026 | Purchase | 40,690 | $3.88 | $158.0K | 12.11M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 17, 2026 | Purchase | 40,114 | $3.57 | $143.3K | 12.07M | Form 4 ↗ |
BROADWOOD PARTNERS, L.P. 10 percent owner | Apr 17, 2026 | Purchase | 0 | — | — | 12.07M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Insight Molecular Diagnostics Inc.（IMDX）主要由机构投资者持有，机构持股比例约为 60.7%。公司内部人员持股约 72.85%，散户及公众持股约占剩余的 0.00%。
Insight Molecular Diagnostics Inc. 最大机构股东为 BROADWOOD CAPITAL INC，截至 September 30, 2025 持有约 11.41 million 股，占总流通股的 35.62%。
目前共有 27 家机构持有 IMDX 股票，合计持仓市值约 $54,051,121，数据来源为最新 SEC 13F 申报。
常见问题
IMDX ownershipInsight Molecular Diagnostics Inc.（IMDX）主要由机构投资者持有，机构持股约 60.7%。最大股东为 BROADWOOD CAPITAL INC，持股比例 35.62%。内部人员持股约 72.85%。数据来源 SEC Form 13F，截至 September 30, 2025。